FutureChem Co.Ltd (220100) - Cash Flow Conversion Efficiency
Based on the latest financial reports, FutureChem Co.Ltd (220100) has a cash flow conversion efficiency ratio of 0.000x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩13.90 Million ≈ $9.42K USD) by net assets (₩52.79 Billion ≈ $35.78 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 220100 equity financing ratio to measure how much of total assets are equity-financed.
FutureChem Co.Ltd - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how FutureChem Co.Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check 220100 cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
FutureChem Co.Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of FutureChem Co.Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Enea AB
ST:ENEA
|
0.009x |
|
Glintt
LS:GLINT
|
0.004x |
|
Maywood Acquisition Corp. Class A Ordinary Shares
NASDAQ:MAYA
|
-0.002x |
|
CYGNUS Metals Ltd
AU:CY5
|
-0.033x |
|
Jaya Agra Wattie Tbk
JK:JAWA
|
0.023x |
|
Bank Dinar Indonesia Tbk PT
JK:DNAR
|
0.034x |
|
DIRTT Environmental Solutions Ltd.
TO:DRT
|
-0.155x |
|
Genic Co. Ltd
KQ:123330
|
-0.124x |
Annual Cash Flow Conversion Efficiency for FutureChem Co.Ltd (2016–2025)
The table below shows the annual cash flow conversion efficiency of FutureChem Co.Ltd from 2016 to 2025. For the full company profile with market capitalisation and key ratios, see 220100 market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | ₩54.83 Billion ≈ $37.16 Million |
₩-2.43 Billion ≈ $-1.64 Million |
-0.044x | +24.98% |
| 2024-12-31 | ₩54.38 Billion ≈ $36.85 Million |
₩-3.21 Billion ≈ $-2.17 Million |
-0.059x | -1.38% |
| 2023-12-31 | ₩63.91 Billion ≈ $43.31 Million |
₩-3.72 Billion ≈ $-2.52 Million |
-0.058x | +46.36% |
| 2022-12-31 | ₩70.14 Billion ≈ $47.53 Million |
₩-7.61 Billion ≈ $-5.16 Million |
-0.109x | -94.08% |
| 2021-12-31 | ₩52.72 Billion ≈ $35.72 Million |
₩-2.95 Billion ≈ $-2.00 Million |
-0.056x | -6.51% |
| 2020-12-31 | ₩43.37 Billion ≈ $29.39 Million |
₩-2.28 Billion ≈ $-1.54 Million |
-0.052x | +78.37% |
| 2019-12-31 | ₩11.16 Billion ≈ $7.57 Million |
₩-2.71 Billion ≈ $-1.84 Million |
-0.243x | -19.64% |
| 2018-12-31 | ₩16.46 Billion ≈ $11.15 Million |
₩-3.34 Billion ≈ $-2.26 Million |
-0.203x | -94.51% |
| 2017-12-31 | ₩27.20 Billion ≈ $18.43 Million |
₩-2.84 Billion ≈ $-1.92 Million |
-0.104x | -49.37% |
| 2016-12-31 | ₩31.53 Billion ≈ $21.37 Million |
₩-2.20 Billion ≈ $-1.49 Million |
-0.070x | -- |
About FutureChem Co.Ltd
FutureChem Co.,Ltd engages in the research and development, production, and sale of chemicals, pharmaceuticals, and medical devices in South Korea and internationally. The company offers radioactive pharmaceuticals, including [18F]FDG for the treatment of general cancer diagnosis, PDvue for Parkinson's disease, Alzavue for Alzheimer's disease, and FLT for the lung cancer diagnosis. Its products i… Read more